 |
| |
| Jun-01-18 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
| May-30-18 | Downgrade |
Credit Suisse |
Neutral → Underperform |
|
|
| Jan-30-18 | Reiterated |
Morgan Stanley |
Equal-Weight |
$99 → $131 |
|
| Jan-29-18 | Downgrade |
Leerink Partners |
Outperform → Mkt Perform |
|
|
| Oct-30-17 | Reiterated |
Leerink Partners |
Outperform |
$108 → $107 |
|
| Oct-02-17 | Upgrade |
Leerink Partners |
Mkt Perform → Outperform |
|
|
| Sep-25-17 | Downgrade |
UBS |
Buy → Neutral |
$79 → $92 |
|
| Aug-17-17 | Initiated |
Evercore ISI |
Outperform |
$95 |
|
| Jun-22-17 | Upgrade |
Societe Generale |
Hold → Buy |
|
|
| Mar-22-17 | Upgrade |
Societe Generale |
Sell → Hold |
|
|
| Oct-31-16 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
| Oct-18-16 | Initiated |
Leerink Partners |
Mkt Perform |
$70 |
|
| Sep-08-16 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Sep-02-16 | Initiated |
Raymond James |
Outperform |
$82 |
|
| Jun-08-16 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Apr-06-16 | Initiated |
Societe Generale |
Sell |
$47 |
|
| Mar-15-16 | Initiated |
Deutsche Bank |
Hold |
$63 |
|
| Feb-23-16 | Upgrade |
Citigroup |
Neutral → Buy |
|
|
| Dec-01-15 | Downgrade |
Barclays |
Overweight → Equal Weight |
$73 → $72 |
|
| Nov-02-15 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
|
|
| Jun-20-18 08:07AM | 5 Experimental New Drugs That Could Be Worth $47 Billion Motley Fool |
| 06:01AM | Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks Motley Fool |
| Jun-19-18 09:21AM | 8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities" PR Newswire |
| 07:20AM | Wired News AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress ACCESSWIRE |
| 06:32AM | 3 Great Reasons to Buy Gilead Sciences Motley Fool |
| Jun-18-18 06:23PM | Bristol-Myers Posts Data on Empliciti, China Approves Opdivo Zacks |
| 10:30AM | How U.S. tax reform rewards companies that shift profit to tax havens Reuters |
| 08:20AM | Today's Research Reports on Trending Tickers: Canopy Growth and AbbVie ACCESSWIRE |
| Jun-17-18 12:03PM | Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming Motley Fool |
| Jun-15-18 10:26AM | MARKETS: Here's why stocks are dropping right now Yahoo Finance Video |
| 09:27AM | Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals Zacks |
| 09:01AM | 3 High-Yield Stocks at Rock-Bottom Prices Motley Fool |
| 08:18AM | Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc Motley Fool |
| 07:35AM | Analysis: Positioning to Benefit within Canopy Growth, Aurora Cannabis, CannTrust, AbbVie, Cronos Group, and Scotts Miracle-Gro Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| 02:45AM | AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress PR Newswire |
| Jun-14-18 06:52PM | AbbVie Declares Quarterly Dividend PR Newswire |
| Jun-13-18 06:01AM | Humira's Sales Will Decline -- and It's Fantastic News for AbbVie Motley Fool |
| Jun-12-18 06:38PM | AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) PR Newswire |
| Jun-11-18 10:00AM | Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval Zacks |
| 09:37AM | JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space Zacks |
| 09:08AM | The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie Zacks |
| Jun-10-18 05:29PM | The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga |
| 09:40AM | 3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate Motley Fool |
| Jun-09-18 08:36AM | 4 Dividends That Make The World A Better Place Forbes |
| Jun-08-18 02:55PM | AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy PR Newswire |
| 10:27AM | Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant Zacks |
| Jun-07-18 11:30AM | [$$] Big Pharma's Tempting Payouts Barrons.com |
| Jun-06-18 09:24AM | Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive Zacks |
| 08:29AM | ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks |
| 06:02AM | 2 Cheap Dividend Stocks You Can Buy Right Now Motley Fool |
| Jun-05-18 09:16AM | AbbVie's rheumatoid arthritis drug succeeds in late-stage study Reuters |
| 08:30AM | Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis PR Newswire |
| Jun-04-18 08:30AM | Today's Research Reports on Trending Tickers: AbbVie and TherapeuticsMD ACCESSWIRE |
| 08:00AM | AbbVie Announces Final Results of Tender Offer PR Newswire |
| Jun-03-18 05:52PM | Benzinga's Bulls & Bears Of The Week: AbbVie, Lululemon, Netflix, Snap And More Benzinga |
| 10:45AM | Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL) PR Newswire |
| Jun-01-18 04:45PM | Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone PR Newswire |
| 01:47PM | How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales Investor's Business Daily |
| 09:15AM | Solid Month Ends with New Round of Trade Fears Zacks |
| 09:03AM | Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod Reuters |
| 08:54AM | Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod Reuters |
| May-31-18 11:24AM | Traders Are Furious After Computer Botches Stock Sale Bloomberg |
| 09:05AM | Thursdays Vital Data: Micron Technology, Inc. (MU), Bank of America Corp (BAC) and AbbVie Inc. (ABBV) InvestorPlace |
| 08:00AM | AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress PR Newswire |
| May-30-18 04:46PM | AbbVie Announces Updated Preliminary Results of Tender Offer PR Newswire |
| 04:36PM | Why AbbVie's Blockbuster Humira Is Already In Trouble This Year Investor's Business Daily |
| 12:28PM | Credit Suisse Downgrades AbbVie On Humira Competitive Concerns Benzinga |
| 08:00AM | AbbVie Announces Preliminary Results of Tender Offer PR Newswire |
| 06:01AM | Is AbbVie Inc. (ABBV) a Buy? Motley Fool |
| May-29-18 09:57AM | What's in Store for Cooper Companies' (COO) Q2 Earnings? Zacks |
| 08:00AM | AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference PR Newswire |
| May-28-18 02:46AM | AbbVie (ABBV) Up 5.9% Since Earnings Report: Can It Continue? Zacks |
| May-25-18 09:24AM | AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint Zacks |
| May-24-18 04:14PM | AbbVie Is The Amazon Of Biopharma But Can It Keep Going? Investor's Business Daily |
| 09:00AM | IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint PR Newswire |
| 08:35AM | Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock? Zacks |
| 08:00AM | Wired News CytomX Gets FDA Approval for Investigational New Drug Application, Triggers $25 Million Milestone Payment from AbbVie ACCESSWIRE |
| May-23-18 06:01AM | Better Buy: AbbVie Inc. vs. Pfizer Inc. Motley Fool |
| May-22-18 10:30AM | AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico PR Newswire |
| 08:00AM | AbbVie to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire |
| 07:47AM | The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo Zacks |
| May-21-18 02:25PM | Roche (RHHBY) Announces Positive Data on Hemophilia Drug Zacks |
| 10:53AM | Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo Zacks |
| 07:15AM | Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space ACCESSWIRE |
| May-18-18 08:15AM | 5 Things AbbVie Investors Need to Know Motley Fool |
| May-16-18 04:59PM | AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting PR Newswire |
| May-15-18 05:09PM | Trumps Attempt to Shame Drugmakers Shows Medicare Costs Soaring Bloomberg |
| 06:00AM | 3 Top Healthcare Stocks to Buy in May Motley Fool |
| May-14-18 01:25PM | The Trump Plan To Reduce Prescription Drug Prices Will Have A Major Impact Forbes |
| May-11-18 04:02PM | Why Do 113 Top-Rated Funds Own Shares In This Breakout Cloud Stock? Investor's Business Daily |
| May-10-18 06:49PM | 3 Dividend Stocks for In-the-Know Investors Motley Fool |
| May-09-18 06:00AM | 3 Top Biotech Stocks to Buy in May Motley Fool |
| May-08-18 08:00AM | AbbVie to Present at the UBS Global Healthcare Conference PR Newswire |
| May-04-18 04:06PM | Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication Zacks |
| 07:00AM | Is Gilead Sciences Stock Finally a Bargain? Motley Fool |
| May-03-18 01:58PM | Top 5 Biotech Stocks for 2018 Investopedia |
| 10:23AM | Did Gilead Sciences Make a Big Mistake? Motley Fool |
| 10:15AM | NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth Zacks Small Cap Research |
| 09:11AM | Drugmakers eye a new threat to sales but say it hasnt affected them yet MarketWatch |
| 08:45AM | Your first trade for Thursday, May 3 CNBC |
| May-02-18 05:59PM | "Fast Money" final trades: SNAP, SPOT and more CNBC Videos |
| 05:15PM | Top 4 Marijuana Stocks to Watch Investopedia |
| 01:39PM | 9 Winning Stocks as the Bull Loses Steam Investopedia |
| 08:00AM | AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference PR Newswire |
| 06:03AM | Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV) Motley Fool |
| 06:01AM | Gilead Sciences' First-Quarter Twist: Weak HIV Sales Motley Fool |
| May-01-18 04:33PM | Seagate, Pfizer and Cummins skid while AbbVie jumps Associated Press +5.72% |
| 04:31PM | Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today Motley Fool |
| 09:32AM | How AbbVie Makes its Money Investopedia |
| 08:45AM | AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis PR Newswire |
| 07:47AM | AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock PR Newswire |
| 04:31AM | [$$] Gilead shares rattled by sharp slide in hepatitis C drug sales Financial Times |
| Apr-30-18 11:35AM | AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology PR Newswire |
| 10:11AM | Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More Zacks |
| Apr-28-18 02:03PM | AbbVie's First Quarter: Can We Quit Worrying About Humira Now? Motley Fool |
| Apr-27-18 08:18AM | 3 Things You Need to Know About AbbVie's Monster Q1 Earnings Motley Fool |
| 08:00AM | AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting PR Newswire |
| Apr-26-18 11:59PM | Edited Transcript of ABBV earnings conference call or presentation 26-Apr-18 1:00pm GMT Thomson Reuters StreetEvents +6.06% |
| 04:29PM | How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily |
| 02:23PM | AbbVie Inc. -- Moody's: AbbVie's share repurchase acceleration credit negative Moody's |
|
|
|
|
| AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| ALBAN CARLOS | EVP, Commercial Operations | Mar 01 | Option Exercise | 29.23 | 48,100 | 1,405,795 | 178,547 | Mar 02 05:29 PM | | CHASE WILLIAM J | EVP, Chief Financial Officer | Mar 01 | Option Exercise | 25.91 | 32,400 | 839,339 | 197,263 | Mar 02 05:28 PM | | Schumacher Laura J | Executive Vice President | Mar 01 | Sale | 117.85 | 25,000 | 2,946,148 | 98,317 | Mar 02 05:28 PM | | CHASE WILLIAM J | EVP, Chief Financial Officer | Mar 01 | Sale | 114.50 | 32,400 | 3,709,687 | 164,863 | Mar 02 05:28 PM | | ALBAN CARLOS | EVP, Commercial Operations | Mar 01 | Sale | 114.39 | 80,995 | 9,264,808 | 97,552 | Mar 02 05:29 PM | | Michael Robert A. | VP, Controller | Feb 28 | Sale | 119.43 | 4,294 | 512,853 | 6,876 | Mar 02 05:31 PM | | SALEKI-GERHARDT AZITA | SVP, Operations | Feb 28 | Sale | 117.77 | 1,337 | 157,458 | 93,312 | Mar 02 05:31 PM | | SEVERINO MICHAEL | EVP, R&D and CSO | Feb 28 | Sale | 117.93 | 2,643 | 311,684 | 132,281 | Mar 02 05:30 PM | | RICHMOND TIMOTHY J. | SVP, Human Resources | Feb 28 | Sale | 118.67 | 18,129 | 2,151,452 | 17,588 | Mar 02 05:30 PM | | CHASE WILLIAM J | EVP, Chief Financial Officer | Feb 28 | Sale | 119.44 | 38,528 | 4,601,954 | 164,863 | Mar 02 05:28 PM | | ALBAN CARLOS | EVP, Commercial Operations | Feb 28 | Sale | 117.85 | 2,579 | 303,928 | 130,447 | Mar 02 05:29 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Feb 28 | Sale | 117.88 | 8,280 | 976,084 | 313,012 | Mar 02 05:28 PM | | Michael Robert A. | VP, Controller | Feb 20 | Sale | 120.31 | 992 | 119,351 | 13,557 | Feb 20 06:08 PM | | RICHMOND TIMOTHY J. | SVP, Human Resources | Dec 18 | Option Exercise | 35.88 | 87,040 | 3,122,995 | 113,118 | Dec 19 06:09 PM | | RICHMOND TIMOTHY J. | SVP, Human Resources | Dec 18 | Sale | 98.45 | 87,040 | 8,569,053 | 26,078 | Dec 19 06:09 PM | | Schumacher Laura J | Executive Vice President | Dec 15 | Option Exercise | 35.88 | 1,143 | 41,011 | 106,875 | Dec 15 05:13 PM | | Schumacher Laura J | Executive Vice President | Dec 14 | Option Exercise | 35.88 | 144,367 | 5,179,888 | 250,099 | Dec 15 05:13 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Nov 21 | Option Exercise | 58.88 | 218,193 | 12,847,204 | 492,030 | Nov 24 04:55 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Nov 21 | Sale | 94.01 | 218,193 | 20,511,800 | 273,837 | Nov 24 04:55 PM | | SEVERINO MICHAEL | EVP, R&D and CSO | Nov 10 | Sale | 94.69 | 25,633 | 2,427,212 | 114,922 | Nov 13 05:26 PM | | Gosebruch Henry O | Chief Strategy Officer | Oct 30 | Sale | 90.55 | 18,300 | 1,657,037 | 65,137 | Oct 31 05:04 PM | | Michael Robert A. | VP, Controller | Sep 28 | Sale | 88.00 | 6,699 | 589,512 | 10,007 | Sep 29 05:02 PM | | SALEKI-GERHARDT AZITA | SVP, Operations | Sep 11 | Option Exercise | 24.21 | 4,800 | 116,199 | 93,099 | Sep 12 05:40 PM | | SALEKI-GERHARDT AZITA | SVP, Operations | Sep 11 | Sale | 85.02 | 8,300 | 705,655 | 84,799 | Sep 12 05:40 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Aug 07 | Option Exercise | 51.42 | 193,131 | 9,930,796 | 469,623 | Aug 08 07:26 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Aug 07 | Sale | 71.00 | 193,131 | 13,713,186 | 276,492 | Aug 08 07:26 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Aug 04 | Option Exercise | 51.42 | 22,038 | 1,133,194 | 364,391 | Aug 04 05:01 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Aug 04 | Sale | 71.07 | 22,038 | 1,566,166 | 276,492 | Aug 04 05:01 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Aug 03 | Option Exercise | 51.42 | 65,861 | 3,386,573 | 342,353 | Aug 04 05:01 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Aug 03 | Sale | 71.00 | 65,861 | 4,676,131 | 298,530 | Aug 04 05:01 PM | | RAPP EDWARD J | Director | Jul 31 | Buy | 70.45 | 4,000 | 281,782 | 15,498 | Aug 02 05:05 PM | | Gosebruch Henry O | Chief Strategy Officer | Jul 31 | Sale | 70.09 | 18,000 | 1,261,638 | 83,737 | Aug 02 05:05 PM | | Gosebruch Henry O | Chief Strategy Officer | Jul 31 | Sale | 70.42 | 300 | 21,127 | 83,437 | Aug 02 05:06 PM |
|
|
|
|
|
|
